Netrin-1 and Placenta Accreta

NCT ID: NCT04683562

Last Updated: 2022-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 34 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-01
• Study Completion Date: 2022-06-01

Brief Summary

Netrin-1 is a secreted protein, which was first identified as a neuronal guidance factor. It is expressed in a multitude of tissues as pancreas, lung, breast, and placenta. Netrin-1 is a multifunctional protein, involved in cell polarity, adhesion, angiogenesis, apoptosis, migration, morphogenesis, and differentiation of various cell types. Most of netrin-1 activity occur through signaling pathways induced by its two main receptors, DCC (deleted in colorectal cancer) and UNC5H (uncoordinated-5 homolog). Its receptors have been linked to the processes of apoptosis and angiogenesis. In absence of netrin-1, DCC and UNC5H receptors lead to apoptosis. In contrary, in presence of netrin-1, receptors transduce molecular cascades leading to proliferation, differentiation and migration of the cells. Netrin-1 has been involved in the pathogenesis of multiple diseases, as diabetes, cardiovascular diseases, and cancer. Serum Netrin-1 levels were high in preeclamptic patients.

Conditions

Placenta Accreta

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Normal pregnancy group

Group Type: OTHER

Pregnant women at 28-32 weeks

Intervention Type: OTHER

Pregnant women at gestational age 28-32 weeks

at delivery

Intervention Type: OTHER

women delivered at term

Placenta accreta group

Group Type: OTHER

Pregnant women at 28-32 weeks

Intervention Type: OTHER

Pregnant women at gestational age 28-32 weeks

at delivery

Intervention Type: OTHER

women delivered at term

Interventions

Pregnant women at 28-32 weeks

Pregnant women at gestational age 28-32 weeks

Intervention Type: OTHER

at delivery

women delivered at term

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age between 20-40 years.
• Singleton pregnancy.
• Women with suspicion of PA by two-dimensional (2D) gray scale imaging and color Doppler flow mapping

Exclusion Criteria

• Multiple pregnancy,
• Fetal anomalies,
• Preterm premature rupture of membranes, or infection
• Any medical disorders, such as thyroid dysfunction, hypertension, and gestational diabetes
• Patients with known bleeding disorders or on anticoagulant therapy.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Mohammed Khairy Ali

Assistant professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Woman's Health Hospital

Asyut, , Egypt

Countries

Egypt

Other Identifiers

PA-NT1

Identifier Type: -

Identifier Source: org_study_id